½ÃÀ庸°í¼­
»óǰÄÚµå
1587526

À§Ã¼·ù ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : À¯Çüº°, Á¦Çüº°, À¯Åë ä³Îº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)

Gastroretentive Drug Delivery Systems Market Size, Share & Trends Analysis Report By Type (Floating, Expandable), By Dosage (Tablets, Capsule, Gel, Liquid), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 100 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

À§Ã¼·ù ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå ¼ºÀå ¹× µ¿Çâ:

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é, ¼¼°è À§Ã¼·ù ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå ±Ô¸ð´Â 2025³âºÎÅÍ 2030³â±îÁö 6.4%ÀÇ CAGRÀ» ±â·ÏÇÏ¿© 2030³â±îÁö 227¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼ÒÈ­°ü È®ÀåÇü ¾à¹°Àü´Þ ½Ã½ºÅÛ(DDS)Àº Èí¼ö°¡ »óºÎ ¼ÒÈ­°ü(GIT)¿¡ ±¹ÇѵǾî È¿À²ÀûÀ¸·Î Àü´ÞµÉ ¼ö Àֱ⠶§¹®¿¡ »ýü ÀÌ¿ë·üÀÌ ³·Àº ¾à¹°¿¡ ÀÌÁ¡À» Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼­ Àý´ëÀûÀÎ »ýü ÀÌ¿ë·üÀ» ³ôÀ̰í Èí¼ö¸¦ ±Ø´ëÈ­ÇÏ´Â °ÍÀÌ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ·¯ÇÑ DDSÀÇ ¸î °¡Áö ÀåÁ¡Àº Ä¡·á È¿À²°ú ¾à¹°ÀÇ »ýü ÀÌ¿ë·üÀ» Çâ»ó½ÃŰ´Â °ÍÀÔ´Ï´Ù. ÅëÁ¦µÇ°í ü°èÀûÀÎ DDS´Â Áúº´ ºÎÀ§¿¡¼­ ¾à¹°ÀÌ °úµµÇÏ°Ô ³ëÃâµÉ °¡´É¼ºÀ» ÃÖ¼ÒÈ­ÇÕ´Ï´Ù. ¶ÇÇÑ Ã¼³» ¾à¹° ´ë»ç°¡ ¾ïÁ¦µÇ¾î ´õ ³ôÀº Ä¡·á È¿°ú¸¦ ±â´ëÇÒ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼­ À§³» ü·ù¼º DDS¿Í °ü·ÃµÈ ´Ù¾çÇÑ ÀÌÁ¡ÀÌ Àüü ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

DDS´Â ¾à¹°ÀÇ ¹æÃâÀ» À¯ÁöÇÏ¿© ¼ÒÀå°ú À§Àå¿¡¼­ ±¹¼Ò Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÀÌ ¹æ¹ýÀº ¼ÒÀå°ú À§Àå°ú °ü·ÃµÈ ´Ù¾çÇÑ ÁúȯÀÇ Ä¡·á¿¡ À¯¿ëÇÕ´Ï´Ù. À§ ¹× ¼ÒÀå °ü·Ã ÁúȯÀÇ Áõ°¡·Î ÀÎÇØ ÀÌ·¯ÇÑ È¿À²ÀûÀÎ DDS¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ³»½Ã°æ ¼¾ÅÍ¿¡ µû¸£¸é ¸Å³â ¾à 6,200¸¸ ¸íÀÌ ¼ÒÈ­±â ÁúȯÀ¸·Î Áø´Ü¹Þ°í ÀÖ½À´Ï´Ù. ´ëºÎºÐÀÇ ¼ÒÈ­±â ÁúȯÀÇ À¯º´·üÀº ¿¬·É¿¡ µû¶ó Áõ°¡ÇÏ¿© ¼ºÀΰú ³ë³âÃþ¿¡ ´ëÇÑ »õ·Î¿î ÇコÄÉ¾î ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ DDS´Â À§ Á¡¸·ÇÏ Á¶Á÷¿¡ ±í¼÷ÀÌ ¹¯Çô ÀÖ´Â Ç︮ÄÚ¹ÚÅÍ ÆÄÀϷθ®±ÕÀ» Á¦°ÅÇÏ¿© ½Äµµ¿°À» Æ÷ÇÔÇÑ ½ÊÀÌÁöÀå ±Ë¾ç°ú À§±Ë¾ç Ä¡·á¿¡ È¿°úÀûÀÔ´Ï´Ù. À̿ʹ º°µµ·Î GRDDS´Â À§Àå¿¡¼­ õõÈ÷ ¾à¹°À» ¹æÃâÇÏ¿© Àü½Å ¼øÈ¯¿¡¼­ À¯È¿ ³óµµ¸¦ ¿À·§µ¿¾È À¯ÁöÇÕ´Ï´Ù. µû¶ó¼­ À§ÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ½ÃÀå È®´ë°¡ ¿¹»óµË´Ï´Ù.

À§Ã¼·ù ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®:

  • ºÎÀ¯¼º ¾à¹°Àü´Þ ½Ã½ºÅÛÀÌ 2024³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
  • ÀÌ ½Ã½ºÅÛÀº À§¾×º¸´Ù ¹Ðµµ°¡ ³·±â ¶§¹®¿¡ À§ ¹èÃâ ¼Óµµ¸¦ º¯°æÇÏÁö ¾Ê°í ¿À·§µ¿¾È À§Àå¿¡ ¶° ÀÖ½À´Ï´Ù.
  • ¾×»óÇü Á¦Ç° À¯ÇüÀº ¸ðµç À¯ÇüÀÇ À§Àå Àå¾Ö Ä¡·á¿¡ ¾×»óÇü À§³» ü·ù¼º Á¦Ç°ÀÌ ±¤¹üÀ§ÇÏ°Ô »ç¿ë °¡´ÉÇϱ⠶§¹®¿¡ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ¿Â¶óÀÎ ¾à±¹ ºÎ¹®Àº »ó¼¼ÇÑ ÀǾàǰ Á¤º¸¿Í ÇÔ²² ´Ù¾çÇÑ ¼±ÅñÇÀ» Á¦°øÇϱ⠶§¹®¿¡ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ºÏ¹Ì°¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖÀ¸¸ç, ¿¹Ãø ±â°£ µ¿¾È¿¡µµ ±× ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ÀÌ´Â Ç︮ÄÚ¹ÚÅÍ ÆÄÀϷθ®±Õ °¨¿° À¯º´·ü Áõ°¡, ¿¬±¸°³¹ßºñ Áõ°¡, À§Åõ°ú¼º DDSÀÇ ±â¼úÀû Áøº¸¿¡ ±âÀÎÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå À§Ã¼·ù ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ºñÁî´Ï½º ȯ°æ ºÐ¼®
    • ¾÷°è ºÐ¼® - Porter's Five Forces ºÐ¼®
    • PESTLE ºÐ¼®

Á¦4Àå À§Ã¼·ù ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå : À¯Çüº° ºñÁî´Ï½º ºÐ¼®

  • À¯Çüº° ½ÃÀå Á¡À¯À², 2024³â°ú 2030³â
  • À¯Çü ºÎ¹® ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®, À¯Çüº°, 2018-2030³â
  • ºÎÀ¯¼º ¾à¹°Àü´Þ ½Ã½ºÅÛ
  • È®Àå °¡´ÉÇÑ ¾à¹°Àü´Þ ½Ã½ºÅÛ
  • »ýü Á¢Âø¼º ¾à¹°Àü´Þ ½Ã½ºÅÛ
  • °í¹Ðµµ ½Ã½ºÅÛ
  • ±âŸ

Á¦5Àå À§Ã¼·ù ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå : Á¦Çüº° ºñÁî´Ï½º ºÐ¼®

  • Á¦Çü ½ÃÀå Á¡À¯À², 2024³â ¹× 2030³â
  • Á¦Çü ºÎ¹® ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®, Á¦Çüº°, 2018-2030³â
  • Á¤Á¦
  • ĸ½¶
  • °Ö
  • ¾×ü
  • ±âŸ

Á¦6Àå À§Ã¼·ù ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå : À¯Åë ä³Îº° ºñÁî´Ï½º ºÐ¼®

  • À¯Åë ä³Î ½ÃÀå Á¡À¯À², 2024³â ¹× 2030³â
  • À¯Åë ä³Î ºÎ¹® ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®, À¯Åë ä³Îº°, 2018-2030³â
  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦7Àå À§Ã¼·ù ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå : À¯Çü, Á¦Çü, À¯Åë ä³Îº° Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®

  • Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â ¹× 2030³â
  • Áö¿ª ½ÃÀå ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð, ¿¹Ãø µ¿Ç⠺м®, 2018³â¿¡¼­ 2030³â :
  • ºÏ¹Ì
    • ±¹°¡º°, 2018-2030³â
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • ±¹°¡º°, 2018-2030³â
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ³ë¸£¿þÀÌ
    • µ§¸¶Å©
    • ½º¿þµ§
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ±¹°¡º°, 2018-2030³â
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ±¹°¡º°, 2018-2030³â
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ±¹°¡º°, 2018-2030³â
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • Äí¿þÀÌÆ®

Á¦8Àå °æÀï »óȲ

  • Âü¿©ÀÚ °³¿ä
  • ±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Ç ºÐ¼®
  • ±â¾÷ ºÐ·ù
  • Àü·« ¸ÅÇÎ
  • ±â¾÷ °³¿ä/»óÀå ±â¾÷
    • Catalent, Inc
    • Lonza
    • Evonik Industries AG
    • Colorcon
    • Quotient Sciences
    • AptarGroup, Inc.
    • Aenova Holding GmbH
    • Evotec SE
    • Vectura Group Ltd
    • Ashland
ksm 24.11.21

Gastroretentive Drug Delivery Systems Market Growth & Trends:

The global gastroretentive drug delivery systems market size is expected to reach USD 22.7 billion by 2030, registering a CAGR of 6.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. Gastroretentive Drug Delivery Systems (DDSs) offer possible advantages for the drug with poor bioavailability, as their absorption is restricted to the upper Gastrointestinal Tract (GIT) and can be delivered proficiently. Hence enhancing absolute bioavailability and maximizing its absorption is expected to boost market growth during the forecast period.

Several advantages of these DDSs include curative efficiency and an increase in the bioavailability of drugs. The controlled and systematic DDS minimizes the chances of medicine overexposure at the diseased site. It also offers higher efficiency owing to reduced counter activity by the body. Hence, various advantages associated with gastroretentive DDSs are expected to foster the overall market progression.

The DDS sustains the release of drugs and avails local therapy in the small intestine and stomach. The method is useful in the treatment of various disorders related to the small intestine and stomach. Rising cases of stomach and small intestine-related disorders are anticipated to foster the demand for such efficient DDSs. According to the Endoscopy Center, each year around 62.0 million people are diagnosed with digestive disorders. The prevalence of most digestive disorders increases with age, creating demand for novel healthcare systems among adults and the geriatric population.

These DDSs are effective in treating duodenal and gastric ulcers, including esophagitis, by eliminating deeply buried helicobacter pylori from the submucosal tissue of the stomach. Apart from this, GRDDSs release the medicine slowly in the stomach and preserve its effective concentration in systemic circulation for a prolonged period of time. Hence, the above-mentioned factors are predicted to augment market expansion.

Gastroretentive Drug Delivery Systems Market Report Highlights:

  • The floating drug delivery systems held the largest market share in 2024.
  • These systems have a lower density than gastric fluids and hence stay buoyant in the stomach without altering the gastric emptying rate for a long time.
  • The liquid dosage form segment is expected to grow at the fastest rate during the forecast period due to the availability of a wide range of liquid-based gastroretentive products in treating all types of gastric disorders.
  • The online pharmacies segment is predicted to witness the fastest growth rate over the forecast timeframe as they offer a wide range of options along with in-depth drug information.
  • North America held the largest market share and is anticipated to maintain its dominance over the forecast period.
  • This is attributable to the growing prevalence of H. Pylori infection, increasing R&D expenditure, and rising technological advancements in gastroretentive DDSs.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Dosage
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Gastroretentive Drug Delivery Systems Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Gastroretentive Drug Delivery Systems Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Floating Drug Delivery System
    • 4.4.1. Floating Drug Delivery System Market, 2018 - 2030 (USD Million)
  • 4.5. Expandable Drug Delivery System
    • 4.5.1. Expandable Drug Delivery System Market, 2018 - 2030 (USD Million)
  • 4.6. Bioadhesive Drug Delivery System
    • 4.6.1. Bioadhesive Drug Delivery System Market, 2018 - 2030 (USD Million)
  • 4.7. High Density Systems
    • 4.7.1. High Density Systems Market, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Gastroretentive Drug Delivery Systems Market: Dosage Business Analysis

  • 5.1. Dosage Market Share, 2024 & 2030
  • 5.2. Dosage Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Dosage, 2018 to 2030 (USD Million)
  • 5.4. Tablets
    • 5.4.1. Tablets Market, 2018 - 2030 (USD Million)
  • 5.5. Capsule
    • 5.5.1. Capsule Market, 2018 - 2030 (USD Million)
  • 5.6. Gel
    • 5.6.1. Gel Market, 2018 - 2030 (USD Million)
  • 5.7. Liquid
    • 5.7.1. Liquid Market, 2018 - 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Gastroretentive Drug Delivery Systems Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2030
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 7. Gastroretentive Drug Delivery Systems Market: Regional Estimates & Trend Analysis by Type, Dosage, and Distribution Channel

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Gastroretentive Drug Delivery Systems Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Gastroretentive Drug Delivery Systems Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Gastroretentive Drug Delivery Systems Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Gastroretentive Drug Delivery Systems Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Gastroretentive Drug Delivery Systems Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Gastroretentive Drug Delivery Systems Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Gastroretentive Drug Delivery Systems Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Gastroretentive Drug Delivery Systems Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Gastroretentive Drug Delivery Systems Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Gastroretentive Drug Delivery Systems Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Norway
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Norway Gastroretentive Drug Delivery Systems Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Denmark Gastroretentive Drug Delivery Systems Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Sweden
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Sweden Gastroretentive Drug Delivery Systems Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Gastroretentive Drug Delivery Systems Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Gastroretentive Drug Delivery Systems Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Gastroretentive Drug Delivery Systems Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Gastroretentive Drug Delivery Systems Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Gastroretentive Drug Delivery Systems Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Gastroretentive Drug Delivery Systems Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Gastroretentive Drug Delivery Systems Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Gastroretentive Drug Delivery Systems Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Gastroretentive Drug Delivery Systems Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Gastroretentive Drug Delivery Systems Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Gastroretentive Drug Delivery Systems Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Gastroretentive Drug Delivery Systems Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Gastroretentive Drug Delivery Systems Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Gastroretentive Drug Delivery Systems Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Gastroretentive Drug Delivery Systems Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Catalent, Inc
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Lonza
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Evonik Industries AG
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Colorcon
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Quotient Sciences
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. AptarGroup, Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Aenova Holding GmbH
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Evotec SE
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Vectura Group Ltd
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Ashland
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦